MedTrace Logo

Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines

NCT01237977 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 314

Last updated 2019-03-28

No results posted yet for this study

Summary

The purpose of this study is to test the hypothesis that the efficacy and safety of Meditoxin® are not inferior to Botox®'s in the treatment of glabellar lines.

Conditions

  • Skin Aging

Interventions

DRUG

Botulinum Toxin Type A(Meditoxin®)

single administration, Day 0, 20U

DRUG

Botulinum Toxin Type A(Botox®)

single administration, Day 0, 20U

Sponsors & Collaborators

  • Medy-Tox

    lead INDUSTRY

Principal Investigators

  • Chang-Hun Huh, MD, Ph.D. · Seoul National University Bundang Hospital

  • Hoon Kang, MD, Ph.D. · St. Paul Hospital

  • Won-Seok Kim, MD, Ph.D. · Kang-Buk Samsung Medical Center

  • Jong-Hyun Won, MD, Ph.D. · Seoul Asan Medical Center

  • Joo-Hee Lee, MD, Ph.D. · Sevrance Medical Center

  • Beom-Joon Kim, MD, Ph.D. · Chung-Ang University Yong-San Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-23
Primary Completion
2010-08-30
Completion
2010-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01237977 on ClinicalTrials.gov